Oraycea (Doxycycline)

Doxycycline, the active ingredient in Oraycea, is a tetracycline antibiotic presented as a unknown strength/unknown form for oral use. It treats a variety of bacterial infections in adults and children when appropriate. GNH USA supplies Oraycea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oraycea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oraycea is a broad‑spectrum tetracycline that acts on bacterial pathogens responsible for several infectious disease categories.

- Acne vulgaris: reduces inflammatory lesions and bacterial colonisation of the skin. - Community‑acquired pneumonia: provides coverage against typical and atypical respiratory pathogens. - Uncomplicated urinary tract infection: eradicates susceptible uropathogens causing cystitis. - Lyme disease early disseminated stage: targets Borrelia burgdorferi to prevent disease progression. - Chlamydial infection: treats genital tract infections caused by Chlamydia trachomatis. - Traveler’s diarrhea caused by susceptible enteric bacteria : an effective oral therapy for mild gastro‑intestinal infections.

Doxycycline may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea or upset stomach. - Diarrhea or loose stools. - Photosensitivity leading to easy sunburn. - Oral or vaginal candidiasis. - Mild headache. - Skin rash or itching.

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis. - Hepatotoxicity presenting with jaundice. - Intracranial hypertension (pseudotumor cerebri). - Blood dyscrasias including neutropenia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute pancreatitis.

Before prescribing Oraycea, clinicians should consider several safety aspects.

- Pregnancy: avoid use in the second and third trimesters due to fetal tooth discoloration risk. - Breastfeeding: caution advised as doxycycline is excreted in milk. - Children <8 years: contraindicated because of permanent tooth staining. - Liver or kidney impairment: dose adjustment may be required. - Concomitant use with anticoagulants: monitor INR closely. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Doxycycline can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antacids containing aluminium, magnesium or calcium: reduce doxycycline absorption. - Oral iron supplements: chelate doxycycline and markedly decrease its bioavailability. - Broad‑spectrum tetracyclines (e.g., minocycline): additive toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Retinoids (isotretinoin, acitretin): increase risk of intracranial hypertension. - Carbamazepine and phenytoin: may accelerate doxycycline metabolism, lowering plasma levels.